主页 > 医学文档 >
【medical-news】干细胞移植接受者将面临长期的癌
Long-term cancer risk follows stem cell transplant recipients
Hematopoietic stem cell transplant (HSCT) recipients face a significant long-term risk for developing a second cancer, particularly if they were older at the time of transplant or received stem cells from a female donor, according to a new study. Published in the January 1, 2007 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, the study reveals that within 10 years of an allogeneic HSCT, the relative risk of a second, solid cancer is almost twice that of the general population. In addition, cancer risk almost quadruples for patients who were over 40 years old at the time of transplant or for patients who received stem cells from a female donor.
Myeloablative, allogeneic HSCT is an effective standard therapy for specific life-threatening diseases, such as leukemia or myelodysplastic syndrome, for which blood cell lineages (which originate principally in the bone marrow and circulate in the blood) are abnormal. Destroying the patient's own unhealthy stem cells in the bone marrow and replacing them with a compatible donor's stem cells offers the chance of cure for a disease that otherwise has a high mortality rate with non-transplant therapies. While the procedure can be lifesaving, it is associated with serious short-term adverse effects, such as mucostitis, infections, and liver vascular obstruction as well as the potential long-term complication of developing of a second, usually solid cancer.
To estimate the risk and identify risk factors associated with this outcome, Genevieve Gallagher, M.D. and Donna L. Forrest, M.D. of the BC Cancer Agency and the University of British Columbia, retrospectively reviewed the medical records of 926 patients treated with myeloablative stem cell transplants over an 18-year period.
They found that at their institution the 10-year incidence of second cancers in these patients was 3.1 percent. When nonmelanoma skin cancer and carcinoma in situ of the cervix were excluded, incidence was 2.3 percent. That risk was 1.85 times that of the general population. The median time to diagnosis was almost 7 years after transplant. The most commonly reported second cancers were cancers of the skin (basal and squamous cell), lung, oral cavity, and colon.
Furthermore, data analysis showed that the risk more than tripled for patients who received their transplant when they were over 40 years of age. The study also identified a new risk factor: patients who received stem cells from a female donor had almost quadrupled the risk of a second solid cancer, a risk that further increased when the patient was male. "This observation has not been previously reported in the literature and the explanation for this finding is uncertain," say the authors.
"Since the risk of developing a solid neoplasm post-allogeneic transplantation continues to increase with time," suggest the authors, "extended follow-up will be needed to more fully assess the incidence and risk factors for their development." 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 今天临时有事，估计无法明天无法提交，请其他战友认领吧。 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 http://www.dxy.cn/bbs/post/view?bid=116&id=7631658&sty=1
重复. 已经有人完成了. 不会吧，我刚翻译完了，居然是翻译过了的！？
Long-term cancer risk follows stem cell transplant recipients
干细胞移植接受者将面临长期的癌症风险
Hematopoietic stem cell transplant (HSCT) recipients face a significant long-term risk for developing a second cancer, particularly if they were older at the time of transplant or received stem cells from a female donor, according to a new study. Published in the January 1, 2007 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, the study reveals that within 10 years of an allogeneic HSCT, the relative risk of a second, solid cancer is almost twice that of the general population. In addition, cancer risk almost quadruples for patients who were over 40 years old at the time of transplant or for patients who received stem cells from a female donor.
根据最新的一项研究，造血干细胞移植（HSCT）患者面临显著升高的发生继发癌的长期风险，尤其是老年移植患者或接受女性供体干细胞移植的患者。一项研究结果将发表在经过美国癌症学会同侪评鉴的《癌症》杂志2007年1月1日期上 (http://www.interscience.wiley.com/cancer-newsroom)。该研究显示在同种异体造血干细胞移植后10年之内，继发实体癌的相关风险大约是普通人的2倍。此外，40岁以上的或接受女性供体干细胞移植的患者癌症发病风险约为4倍。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-01 05:11
医学,生命科学网